RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE.
Retatrutide is an investigational peptide engineered to activate the GIP, GLP-1, and glucagon receptors. It has been studied by independent investigators as a triple-receptor agonist in metabolic research.
Research background: Jastreboff et al. reported a 48-week, randomized Phase 2 human trial evaluating an independently manufactured investigational retatrutide product in adults with obesity. The study examined changes in body weight, cardiometabolic measures, and adverse events. This publication does not evaluate any Amino Fusion Labs material.
Primary study: Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine (2023).
https://pubmed.ncbi.nlm.nih.gov/37366315/
This citation is provided solely as scientific background. It does not establish the identity, purity, quality, safety, effectiveness, FDA approval, or suitability of this product and is not a recommendation for human use.
This product has not been evaluated or approved by the U.S. Food and Drug Administration. It is not intended for ingestion, injection, inhalation, topical application, compounding, diagnostic use, therapeutic use, or any other administration to humans or animals. Amino Fusion Labs provides no medical advice, dosing guidance, reconstitution instructions, or administration instructions.
SUPPLIED AS LYOPHILIZED POWDER. For qualified laboratory research only. Any preparation or handling must follow an authorized laboratory’s validated protocol. Not for human or veterinary use. No dosing, reconstitution, compounding, or administration instructions are provided.
RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE.
Retatrutide is an investigational peptide engineered to activate the GIP, GLP-1, and glucagon receptors. It has been studied by independent investigators as a triple-receptor agonist in metabolic research.
Research background: Jastreboff et al. reported a 48-week, randomized Phase 2 human trial evaluating an independently manufactured investigational retatrutide product in adults with obesity. The study examined changes in body weight, cardiometabolic measures, and adverse events. This publication does not evaluate any Amino Fusion Labs material.
Primary study: Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine (2023).
https://pubmed.ncbi.nlm.nih.gov/37366315/
This citation is provided solely as scientific background. It does not establish the identity, purity, quality, safety, effectiveness, FDA approval, or suitability of this product and is not a recommendation for human use.
This product has not been evaluated or approved by the U.S. Food and Drug Administration. It is not intended for ingestion, injection, inhalation, topical application, compounding, diagnostic use, therapeutic use, or any other administration to humans or animals. Amino Fusion Labs provides no medical advice, dosing guidance, reconstitution instructions, or administration instructions.
SUPPLIED AS LYOPHILIZED POWDER. For qualified laboratory research only. Any preparation or handling must follow an authorized laboratory’s validated protocol. Not for human or veterinary use. No dosing, reconstitution, compounding, or administration instructions are provided.